Fred Uthoff
Family Medicine · Sikeston, MONPI 1639164965
Payments from drug & device makers
Across 192 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$501
- Sunovion Pharmaceuticals Inc.$429
- Amgen$401
- Lilly USA, LLC$317
- Mylan Specialty L.p.$218
- Astellas Pharma US Inc$160
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,39195%
- Education$1605%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $501 |
| Sunovion Pharmaceuticals Inc. | 29 | $429 |
| Amgen | 17 | $401 |
| Lilly USA, LLC | 17 | $317 |
| Mylan Specialty L.p. | 14 | $218 |
| Astellas Pharma US Inc | 2 | $160 |
| AbbVie | 8 | $160 |
| Boehringer Ingelheim | 8 | $137 |
| Medtronic(2 entities) | 2 | $133 |
| Novartis | 8 | $125 |
| Dexcom, Inc. | 5 | $116 |
| GSK | 8 | $113 |
| Pfizer | 7 | $108 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Merck | 3 | $41 |
| Grifols USA, LLC | 2 | $37 |
| Bayer | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Lundbeck LLC | 2 | $33 |
| Johnson & Johnson | 2 | $30 |
| AstraZeneca | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| OPKO Pharmaceuticals, LLC | 2 | $25 |
| Sumitomo Pharma America, Inc. | 2 | $24 |
| Abbott | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,551 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 124 | $145,010 |
| EliquisApixaban | 220 | $103,277 |
| OzempicSemaglutide | 102 | $94,242 |
| LinzessLinaclotide | 94 | $56,799 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $51,399 |
| JardianceEmpagliflozin | 78 | $47,504 |
| FarxigaDapagliflozin Propanediol | 68 | $42,046 |
| XareltoRivaroxaban | 78 | $40,865 |
| GemtesaVibegron | 59 | $20,678 |
| Repatha SureclickEvolocumab | 35 | $18,529 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $17,248 |
| VascepaIcosapent Ethyl | 54 | $16,965 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $16,584 |
| MyrbetriqMirabegron | 27 | $16,110 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $15,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $317 | $145,010124 claims |
| PfizerEliquis, Premarin | $108 | $105,986231 claims |
| Novo NordiskOzempic, Rybelsus | $501 | $104,958113 claims |
| GSKTrelegy Ellipta, Arexvy | $113 | $62,399120 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $26 | $58,63192 claims |
| AbbVieLinzess | $160 | $56,79994 claims |
| Boehringer IngelheimJardiance | $137 | $47,50478 claims |
| Johnson & JohnsonXarelto | $30 | $40,86578 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $20,67859 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $15 | $17,24822 claims |
| Astellas Pharma US IncMyrbetriq | $160 | $16,11027 claims |
| MerckJanumet, Belsomra | $41 | $11,57024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Sikeston
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.